COMMUNIQUÉS West-GlobeNewswire

Context Therapeutics Reports Full Year 2023 Operating and Financial Results
21/03/2024
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 [...]
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21/03/2024
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway [...]
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
21/03/2024
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient out of six already enrolled and treated with initial dose of 2.50 mg/kg/ [...]
Theratechnologies entreprend l’augmentation de la dose dans l’essai clinique de phase I sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
21/03/2024
Le comité d’examen médical a approuvé la mise en place du recrutement de la prochaine cohorte de patientes, conformément au protocole d’optimisation des doses Une première patiente du groupe qui en comptera six a déjà [...]
BrightSpring Health Services Recognizes its Valuable and Esteemed Female Leaders and Staff in Celebration of Women’s History Month
21/03/2024
LOUISVILLE, Ky., March 21, 2024 (GLOBE NEWSWIRE) -- This Women’s History Month, BrightSpring Health Services, Inc. (“BrightSpring” or the “BrightSpring Health Services”) (NASDAQ: BTSG) recognizes and celebrates the [...]
XOMA Declares Quarterly Preferred Stock Dividends
21/03/2024
EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s [...]
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
21/03/2024
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended [...]
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
21/03/2024
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid- [...]
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
21/03/2024
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND- [...]
MiNK Reports Fourth Quarter and Year-End 2023 Results
21/03/2024
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapies [...]
Redecan Cannabis Launches New Spring Lineup
21/03/2024
Introducing Space Age Cake Flower and Hemp’d Pre-rolls, Plus the First-of-Its-Kind 'Taster Series' Coming Soon in a Variety 10-Pack of Its Signature Redees Hemp'd Pre-Rolls TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- [...]
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21/03/2024
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in [...]
Castellum, Inc. Announces 2023 Financial Results
21/03/2024
BETHESDA, Md., March 21, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces its [...]
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
21/03/2024
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter [...]
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
21/03/2024
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight [...]
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
21/03/2024
Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 Additional Phase 2 clinical data and initiation of global [...]
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
21/03/2024
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. [...]
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
21/03/2024
~ Achieved PEDMARK ® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI [...]
Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines
21/03/2024
Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing round Financing will enable Nouscom to continue advancing the clinical development of its portfolio of [...]

Pages